Samsung C&T Confirms Samsung Biologics Rights Issue Price at KRW 1.17 Million a Share

PUBT · 1d ago
Samsung C&T Confirms Samsung Biologics Rights Issue Price at KRW 1.17 Million a Share
  • Samsung C&T corrected its disclosure on November 5, 2026, confirming Samsung Biologics’ final share issue price at KRW 1.17 million.
  • The offering comprises 2,270,000 common shares to raise KRW 2.66 trillion for acquiring securities in another company.
  • The correction also changed the offering’s Fair Trade Commission filing requirement from no to yes.
  • Existing shareholders can subscribe November 9–10, 2026; payment is due November 17, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung C&T Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261105800955), on November 05, 2026, and is solely responsible for the information contained therein.